Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the stocks that could 10x over the next 5 years. On March 3, H.C. Wainwright ...

Beam Therapeutics has set its sights on an accelerated approval of its base editing therapy for the severe form of alpha-1 ...

Beam Therapeutics is set to present positive and significant data from the BEACON Phase 1/2 clinical trial of BEAM-101 at a major conference, enhancing visibility and credibility within the scientific ...

Beam is now in the strongest position of all companies advancing a genetic therapy for alpha-1 antitrypsin deficiency, ...

Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the “Contrarius Global Equity Fund”. A copy of the letter can be downloaded here. The ...

Beam to Receive $250 Million in Combined Upfront Payment and Equity Investment, Expected to Extend Beam’s Cash Runway to the Second Half of 2026 CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- ...

Most laser sources produce Gaussian beams that diverge as they propagate. This natural spreading limits their effectiveness in applications that require light to remain concentrated over long ...

The last time I wrote about Beam Therapeutics Inc. (BEAM) it was in a Seeking Alpha article entitled "Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases." I rated the ...

Beam Therapeutics recently announced that it secured a standby license with Kobe University and Bio Palette for key gene-editing patents and confirmed the upcoming resignation of board member Carole ...

CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported financial ...

Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the best innovative stocks to buy according to Wall Street analysts. H.C. Wainwright reiterated a Buy rating and $80 price target for Beam Therapeutics ...